| Year |
Citation |
Score |
| 2024 |
Oldan JD, Schroeder JA, Hoffman-Censits J, Rathmell WK, Milowsky MI, Solnes LB, Nimmagadda S, Gorin MA, Khandani AH, Rowe SP. PET/Computed Tomography Transformation of Oncology: Kidney and Urinary Tract Cancers. Pet Clinics. PMID 38199916 DOI: 10.1016/j.cpet.2023.12.006 |
0.412 |
|
| 2023 |
Mishra A, Gupta K, Kumar D, Lofland G, Sharma AK, Solnes LB, Rowe SP, Forde PM, Pomper MG, Gabrielson EW, Nimmagadda S. Non-invasive PD-L1 quantification using [F]DK222-PET imaging in cancer immunotherapy. Journal For Immunotherapy of Cancer. 11. PMID 37793856 DOI: 10.1136/jitc-2023-007535 |
0.308 |
|
| 2023 |
Holt DP, Kumar D, Nimmagadda S, Dannals RF. An optimized radiosynthesis of [ F]DK222, a PET radiotracer for imaging PD-L1. Journal of Labelled Compounds & Radiopharmaceuticals. PMID 36627757 DOI: 10.1002/jlcr.4012 |
0.316 |
|
| 2021 |
Slania SL, Das D, Lisok A, Du Y, Jiang Z, Mease RC, Rowe SP, Nimmagadda S, Yang X, Pomper MG. Imaging of Fibroblast Activation Protein in Cancer Xenografts Using Novel (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine-Based Small Molecules. Journal of Medicinal Chemistry. PMID 33730493 DOI: 10.1021/acs.jmedchem.0c02171 |
0.329 |
|
| 2019 |
Lesniak WG, Mease RC, Chatterjee S, Kumar D, Lisok A, Wharram B, Kalagadda VR, Emens LA, Pomper MG, Nimmagadda S. Development of [F]FPy-WL12 as a PD-L1 Specific PET Imaging Peptide. Molecular Imaging. 18: 1536012119852189. PMID 31187691 DOI: 10.1177/1536012119852189 |
0.33 |
|
| 2017 |
Shields AF, Jacobs P, Sznol M, Graham MM, Germain R, Lum L, Jaffee E, de Vries EGE, Nimmagadda S, Van den Abbeele AD, Leung D, Wu AM, Sharon E, Shankar LK. Immune Modulation Therapy and Imaging: Workshop Report. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 28818991 DOI: 10.2967/Jnumed.117.195610 |
0.488 |
|
| 2017 |
Lesniak WG, Aboye T, Chatterjee S, Camarero JA, Nimmagadda S. In vivo Evaluation of an Engineered Cyclotide as Specific CXCR4 Imaging Reagent. Chemistry (Weinheim An Der Bergstrasse, Germany). PMID 28771849 DOI: 10.1002/chem.201702540 |
0.33 |
|
| 2016 |
Azad BB, Chatterjee S, Lesniak WG, Lisok A, Pullambhatla M, Bhujwalla ZM, Pomper MG, Nimmagadda S. A fully human CXCR4 antibody demonstrates diagnostic utility and therapeutic efficacy in solid tumor xenografts. Oncotarget. PMID 26848769 DOI: 10.18632/Oncotarget.7111 |
0.331 |
|
| 2015 |
Yang X, Mease RC, Pullambhatla M, Lisok A, Foss C, Wang Y, Shallal H, Edelman H, Hoye AT, Attardo G, Nimmagadda S, Pomper MG. [18F]Fluorobenzoyl-Lysine-Pentanedioic Acid Carbamates: New Scaffolds for PET Imaging of PSMA. Journal of Medicinal Chemistry. PMID 26629713 DOI: 10.1021/Acs.Jmedchem.5B01268 |
0.429 |
|
| 2015 |
Lesniak WG, Sikorska E, Shallal H, Behnam Azad B, Lisok A, Pullambhatla M, Pomper MG, Nimmagadda S. Structural characterization and in vivo evaluation of β-Hairpin peptidomimetics as specific CXCR4 imaging agents. Molecular Pharmaceutics. 12: 941-53. PMID 25590535 DOI: 10.1021/Mp500799Q |
0.355 |
|
| 2014 |
Woodard LE, De Silva RA, Behnam Azad B, Lisok A, Pullambhatla M, G Lesniak W, Mease RC, Pomper MG, Nimmagadda S. Bridged cyclams as imaging agents for chemokine receptor 4 (CXCR4). Nuclear Medicine and Biology. 41: 552-61. PMID 25038987 DOI: 10.1016/J.Nucmedbio.2014.04.081 |
0.314 |
|
| 2012 |
Chen Z, Penet MF, Nimmagadda S, Li C, Banerjee SR, Winnard PT, Artemov D, Glunde K, Pomper MG, Bhujwalla ZM. PSMA-targeted theranostic nanoplex for prostate cancer therapy. Acs Nano. 6: 7752-62. PMID 22866897 DOI: 10.1021/Nn301725W |
0.355 |
|
| 2011 |
Chen Y, Pullambhatla M, Foss CA, Byun Y, Nimmagadda S, Senthamizhchelvan S, Sgouros G, Mease RC, Pomper MG. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 7645-53. PMID 22042970 DOI: 10.1158/1078-0432.Ccr-11-1357 |
0.388 |
|
| 2011 |
Penet MF, Gadiya MM, Krishnamachary B, Nimmagadda S, Pomper MG, Artemov D, Bhujwalla ZM. Metabolic signatures imaged in cancer-induced cachexia. Cancer Research. 71: 6948-56. PMID 21948967 DOI: 10.1158/0008-5472.Can-11-1095 |
0.316 |
|
| 2010 |
Nimmagadda S, Pullambhatla M, Stone K, Green G, Bhujwalla ZM, Pomper MG. Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomography. Cancer Research. 70: 3935-44. PMID 20460522 DOI: 10.1158/0008-5472.Can-09-4396 |
0.346 |
|
| 2009 |
Nimmagadda S, Mangner TJ, Lawhorn-Crews JM, Haberkorn U, Shields AF. Herpes simplex virus thymidine kinase imaging in mice with (1-(2'-deoxy-2'-[18F]fluoro-1-β-D-arabinofuranosyl)-5-iodouracil) and metabolite (1-(2'-deoxy-2'-[18F]fluoro-1-β-D-arabinofuranosyl)-5-uracil). European Journal of Nuclear Medicine and Molecular Imaging. 36: 1987-93. PMID 19506865 DOI: 10.1007/S00259-009-1177-Y |
0.52 |
|
| 2008 |
Chen Y, Foss CA, Byun Y, Nimmagadda S, Pullambhatla M, Fox JJ, Castanares M, Lupold SE, Babich JW, Mease RC, Pomper MG. Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. Journal of Medicinal Chemistry. 51: 7933-43. PMID 19053825 DOI: 10.1021/Jm801055H |
0.358 |
|
| 2008 |
Fu DX, Foss CA, Nimmagadda S, Ambinder RF, Pomper MG. Imaging virus-associated cancer. Current Pharmaceutical Design. 14: 3048-65. PMID 18991718 DOI: 10.2174/138161208786404371 |
0.316 |
|
| 2008 |
Nimmagadda S, Shields AF. The role of DNA synthesis imaging in cancer in the era of targeted therapeutics. Cancer Metastasis Reviews. 27: 575-87. PMID 18512023 DOI: 10.1007/s10555-008-9148-5 |
0.434 |
|
| 2008 |
Nimmagadda S, Ford EC, Wong JW, Pomper MG. Targeted molecular imaging in oncology: focus on radiation therapy. Seminars in Radiation Oncology. 18: 136-48. PMID 18314068 DOI: 10.1016/J.Semradonc.2007.10.009 |
0.359 |
|
| 2007 |
Nimmagadda S, Mangner TJ, Douglas KA, Muzik O, Shields AF. Biodistribution, PET, and radiation dosimetry estimates of HSV-tk gene expression imaging agent 1-(2'-Deoxy-2'-18F-Fluoro-beta-D-arabinofuranosyl)-5-iodouracil in normal dogs. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 48: 655-60. PMID 17401105 DOI: 10.2967/Jnumed.106.036830 |
0.54 |
|
| 2005 |
Nimmagadda S, Mangner TJ, Sun H, Klecker RW, Muzik O, Lawhorn-Crews JM, Douglas KA, Collins JM, Shields AF. Biodistribution and radiation dosimetry estimates of 1-(2'-deoxy-2'-(18)F-Fluoro-1-beta-D-arabinofuranosyl)-5-bromouracil: PET imaging studies in dogs. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 46: 1916-22. PMID 16269607 |
0.542 |
|
| Show low-probability matches. |